CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
Authorised
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Canine parainfluenza virus, strain Manhattan, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Product identification
Medicine name:
CANIGEN PI/L LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS
Active substance:
- Leptospira interrogans, serovar Canicola, strain 601903, Inactivated
- Canine parainfluenza virus, strain Manhattan, Live
- Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated
Target species:
-
Dog
Route of administration:
-
Subcutaneous use
Product details
Active substance and strength:
-
Leptospira interrogans, serovar Canicola, strain 601903, Inactivated4350.00/enzyme-linked immunosorbent assay unit1.00millilitre(s)
-
Canine parainfluenza virus, strain Manhattan, Live4.80/log10 50% cell culture infectious dose1.00millilitre(s)
-
Leptospira interrogans, serovar Icterohaemorrhagiae, strain 601895, Inactivated4250.00/enzyme-linked immunosorbent assay unit1.00millilitre(s)
Pharmaceutical form:
-
Lyophilisate and suspension for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QI07AI08
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Available in:
-
Belgium
Package description:
- Plastic box of 1 vial of lyophilisate and 1 vial of suspension
- Cardbox of 100 vials of lyophilisate and 100 vials of suspension
- Cardbox of 50 vials of lyophilisate and 50 vials of suspension
- Cardbox of 25 vials of lyophilisate and 25 vials of suspension
- Cardbox of 10 vials of lyophilisate and 10 vials of suspension
- Cardbox of 1 vial of lyophilisate and 1 vial of suspension
- Plastic box of 100 vials of lyophilisate and 100 vials of suspension
- Plastic box of 50 vials of lyophilisate and 50 vials of suspension
- Plastic box of 25 vials of lyophilisate and 25 vials of suspension
- Plastic box of 10 vials of lyophilisate and 10 vials of suspension
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
- Virbac
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V509164
Date of authorisation status change:
Reference member state:
-
France
Procedure number:
- FR/V/0311/001
Concerned member states:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Germany
-
Greece
-
Hungary
-
Ireland
-
Italy
-
Latvia
-
Lithuania
-
Luxembourg
-
Netherlands
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it in another language below.
Labelling
This document does not exist in this language (English). You can find it in another language below.
Combined File of all Documents
English (PDF)
Download Published on: 3/11/2025
Updated on: 13/03/2026
eu-puar-frv0311001-mr-rpe294-en.pdf
English (PDF)
Download Published on: 13/03/2026